Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols
References
- 1. B. M. Reid, J. B. Permuth and T. A. Sellers, Epidemiology of ovarian cancer: a review, Cancer Biol. Med. 14 (2017) 9–32; https://doi.org/10.20892/j.issn.2095-3941.2016.0084
- 2. J. Permuth-Wey and T. A. Sellers, 20. Epidemiology of Ovarian Cancer, in Cancer Epidemiology: Modifiable Factors (Ed. M. Verma)/Series: Methods of Molecular Biology472 (2009) 413–437, Springer, New York 2009; https://doi.org/10.1007/978-1-60327-492-0_20
- 3. J. Ledermann, F. Raja, C. Fotopoulou, A. Gonzalez-Martin, N. Colombo and C. Sessa (ESMO guidelines working group), Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up, Ann. Oncol.24 (Suppl. 6) (2013) vi24-vi32. https://doi.org/10.1093/annonc/mdt333
- 4. F. Raja, N. Chopra and J. Ledermann, Optimal first-line treatment in ovarian cancer, Ann. Oncol. 23 (Suppl. 10) (2012) x118-x127; https://doi.org/10.1093/annonc/mds315
- 5. M. Cristea, E. Han, L. Salmon and R. J. Morgan, Review: Practical considerations in ovarian cancer chemotherapy, Ther. Adv. Med. Oncol. 2 (2010) 175–187; https://doi.org/10.1177/1758834010361333
- 6. M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidi and J. P. Ioannidis, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. Cancer Inst.98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj443
- 7. M. A. Bookman (Ed.), GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma, J. Clin. Oncol. 24 (Suppl.) (2006) 5002–5002 (ASCO Annual Meeting Proceedings 2006); https://doi.org/10.1200/jco.2006.24.18_suppl.5002
- 8. J. A. Ledermann and R. S. Kristeleit, Optimal treatment for relapsing ovarian cancer, Ann. Oncol. 21 (Suppl. 7) (2010) vii218-222; https://doi.org/10.1093/annonc/mdq377
- 9. D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. E. Hummer. D. R. Venkatraman and R. Spriggs, Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer, J. Clin. Oncol. 20 (2002) 1238–1247; https://doi.org/10.1200/JCO.2002.20.5.1238
- 10. M. U. Rashid, A. Zaidi, D. Torres, F. Sultan, A. Benner, B. Naqvi, A. R. Shakoori, A. Seidel-Renkert, H. Farooq, S. Narod, A. Amin and U. Hamann, Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients, Int. J. Cancer119 (2006) 2832–2839; https://doi.org/10.1002/ijc.22269
- 11. M. A. Moore, Y. Ariyaratne, F. Badar, Y. Bhurgri, K. Datta, A. Mathew, P. Gangadharan, A. Nandakumar, K. K. Pradhananga, M. H. Talukder, B. B. Yeole and T. Sobue, Cancer epidemiology in South Asia - past, present and future, Asian Pac. J. Cancer Prev. 11 (Suppl. 2) (2010) 49–66.
- 12. Y. Bhurgri, Karachi cancer registry data - implications for the National Cancer Control Program of Pakistan, Asian Pac. J. Cancer Prev.5 (2004) 77–82.
- 13. Ovarian cancer second most common type in Pakistan, The Daily News 2016, https://www.the-news.com.pk/print/105779-Ovarian-cancer-second-most-common-type-inPakistan; last access date July 15, 2018.
- 14. P. Cheema and R. Burkes, Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer, Curr. Oncol.20 (2013) e150; https://doi.org/10.3747/co.20.1226
- 15. E. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer45 (2009) 228–247; https://doi.org/10.1016/j.ejca.2008.10.026
- 16. S. Zhang, F. Liang and I. Tannock, Use and misuse of common terminology criteria for adverse events in cancer clinical trials, BMC Cancer16 (2016) Article ID 392 (6 pages); https://doi.org/10.1186/s12885-016-2408-9
- 17. C. Aghajanian, S. V. Blank, B. A. Goff, P. L. Judson, M. G. Teneriello, A. Husain, M. A. Sovak, J. Yi and L. R. Nycum, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J. Clin. Oncol.30 (2012) 2039–2045; https://doi.org/10.1200/JCO.2012.42.0505
- 18. M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis and J. P. Ioannidis, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. Cancer Inst.98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj443
- 19. S. Pignata, G. Scambia, G. Ferrandina, A. Savarese, R. Sorio, E. Breda, V. Gebbia, P. Musso, L. Frigerio, P. Del Medico, A. V. Lombardi, A. Febbraro, P. Scollo, A. Ferro, S. Tamberi, A. Brandes, A. Ravaioli, M. R. Valerio, E. Aitini, D. Natale, L. Scaltriti, S. Greggi, C. Pisano, D. Lorusso, V. Salutari, F. Legge, M. Di Maio, A. Morabito, C. Gallo and F. Perrone, Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, J. Clin. Oncol.29 (2011) 3628–3635; https://doi.org/10.1200/JCO.2010.33.8566
- 20. R. S. Suidan, C. M. St Clair, S. J. Lee, J. N. Barlin, K. C. Long Roche, E. J. Tanner, Y. Sonoda, R. R. Barakat, O. Zivanovic and D. S. Chi, A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer, Gynecol. Oncol. 134 (2014) 468–472; https://doi.org/10.1016/j.ygyno.2014.07.090
- 21. M. J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, E. Simonsen, G. Stuart, S. Kaye, I. Vergote, R. B. R. Grimshaw, R. J. Atkinson, K. D. Swenerton, C. Trope, M. Nardi, J. Kaern, S. Tumolo, P. Timmers, J. Roy, F. Lhoas, B. Lindvall, M. Bacon, A. Birt, J. E. Andersen, B. Zee, J. Paul, B. Baron and S. Pecorelli, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J. Natl. Cancer Inst.92 (2000) 699–708; https://doi.org/10.1093/jnci/92.9.699
- 22. A. du Bois, H. J. Lück, W. Meier, H. P. Adams, V. Möbus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schröder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn and J. Pfisterer, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J. Natl. Cancer Inst. 95 (2003) 1320–1329; doi 10.1093/jnci/djg036
- 23. R. F. Ozols, B. N. Bundy, B. E. Greer, J. M. Fowler, D. Clarke-Pearson, R. A. Burger, R. S. Mannel, K. DeGeest, E. M. Hartenbach and R. Baergen, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J. Clin. Oncol.21 (2003) 3194–3200; https://doi.org/10.1200/jco.2003.02.153
- 24. M. Fung-Kee-Fung, T. Oliver, L. Elit, A. Oza, H. W. Hirte and P. Bryson, Optimal chemotherapy treatment for women with recurrent ovarian cancer, Curr. Oncol.14 (2007) 195–208.
- 25. Y. Wang, J. Herrstedt, H. Havsteen, R. DePoint Christensen, M. R. Mirza, B. Lund, J. Maenpaa and G. Kristensen, A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer, BMC Cancer14 (2014) Article ID 937 (7 pages); https://doi.org/10.1186/1471-2407-14-937
- 26. L. A. Holmberg, P. Paley and B. Goff, Docetaxel and carboplatin as salvage therapy for first-relapsed, platinum-sensitive, stage III/IV advanced ovarian cancer, Clin. Ovar. Other Gynecol. Cancer7 (2014) 13–17; https://doi.org/10.1016/j.cogc.2014.12.005
- 27. J. M. Gibson, S. Alzghari, C. Ahn, H. Trantham and N. M. La-Beck, The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials, Oncologist18 (2013) 1022–1031; https://doi.org/10.1634/theoncologist.2013-0126
- 28. M. Parmar, J. Ledermann, N. Colombo, A. du Bois, J. F. Delaloye, G. B. Kristensen, S. Wheeler, A. M. Swart, W. Qian, V. Torri, I. Floriani, G. Jayson and A. Lamont, C. Tropé, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet361 (2003) 2099–2106; https://doi.org/10.1016/S0140-6736(03)13718-X
- 29. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stähle, G. Stuart, R. Kimmig, S. Olbricht, T. Le, J. Emerich, W. Kuhn, J. Bentley, C. Jackisch, H. J. Lück, J. Rochon, A. H. Zimmermann and E. Eisenhauer, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J. Clin. Oncol.24 (2006) 4699–4707; https://doi.org/10.1200/JCO.2006.06.0913
- 30. D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, H. P. Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodoulou, P. Papakostas, D. Pectasides and A. M. Dimopoulos, A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study, BMC Med.8 (2010) Article ID 3 (12 pages); https://doi.org/10.1186/1741-7015-8-3
- 31. C. J. Dunton, Management of treatment-related toxicity in advanced ovarian cancer, Oncologist7 (Suppl. 5) (2002) 11–19.
- 32. K. Kudoh, M. Takano, H. Kouta, R. Kikuchi, T. Kita, M. Miyamoto, A. Watanabe, M. Kato, T. Goto and Y. Kikuchi, Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers, Gynecol. Oncol.122 (2011) 233–237; https://doi.org/10.1016/j.ygyno.2011.04.046
Language: English
Page range: 87 - 97
Accepted on: Jul 16, 2018
Published on: Dec 7, 2018
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2018 Saima Sattar, Mobasher Ahmad, Hamid Saeed, Zikria Saleem, Zeeshan Danish, Muhammad Akhlaq, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.